Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Brooklyn ImmunoTherapeutics, Inc. Appoints Roger Sidhu as Chief Medical Officer

09/22/2021 | 10:07am EST

Brooklyn ImmunoTherapeutics, Inc. announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. Prior to joining Brooklyn, Dr. Sidhu served as Vice President, Clinical Development at Kite Pharma. Previously, he held key positions at Roivant Sciences, where he was Chief Medical Officer and Executive Vice President and Head of Research and Development, Cell Design Labs, where he served as Chief Medical Officer, and Amgen, where he served as Global Product General Manager, Translational Sciences.


ę S&P Capital IQ 2021
All news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
12/02Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
AQ
11/29Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Qua..
GL
11/29Brooklyn ImmunoTherapeutics, Inc. Appoints Susan McClatchey as Head of Quality
CI
11/23BROOKLYN IMMUNOTHERAPEUTICS, INC. : Other Events (form 8-K)
AQ
11/19Brooklyn ImmunoTherapeutics Plans Secondary Offering Of 6.28 Million Shares
MT
11/19Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Sec..
AQ
11/12FALSE12-312021Q300007485920.50.50000 : CommonClassAMember2020-12-310000748592btx:CommonUni..
AQ
11/12BROOKLYN IMMUNOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exh..
AQ
11/09Earnings Flash (BTX) BROOKLYN IMMUNOTHERAPEUTICS LLC Posts Q3 Loss $-1.70
MT
10/26BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA : BTX) added to NASDAQ Composite Index
CI
More news
Analyst Recommendations on BROOKLYN IMMUNOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Capitalization 269 M 269 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 10
Free-Float 47,4%
Chart BROOKLYN IMMUNOTHERAPEUTICS, INC.
Duration : Period :
Brooklyn ImmunoTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BROOKLYN IMMUNOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 5,17 $
Average target price 20,00 $
Spread / Average Target 287%
EPS Revisions
Managers and Directors
Howard J. Federoff President, Chief Executive Officer & Director
Sandra Gurrola Chief Financial Officers
Charles R. Cherington Chairman
Kevin A. D'Amour Chief Scientific Officer
Jay Sial Chief Administrative & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
BROOKLYN IMMUNOTHERAPEUTICS, INC.22.54%269
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298